🇺🇸 FDA
Pipeline program

Afimkibart

GA45331

Phase 3 small_molecule active

Quick answer

Afimkibart for Moderately to Severely Active Crohns Disease is a Phase 3 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).

Program details

Company
Hoffmann-La Roche
Indication
Moderately to Severely Active Crohns Disease
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials